Day: December 7, 2019

AUSTIN, Texas, Dec. 07, 2019 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) announced today that it has entered into a definitive agreement with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, to sell XBiotech’s novel antibody (bermekimab) that neutralizes interleukin-1 alpha (IL-1⍺). IL-1⍺ promotes disease-causing inflammation in a wide range of medical conditions. Janssen will acquire all rights to bermekimab under the terms of the agreement, and XBiotech will be free to use its True Human Antibody discovery program to develop new antibody therapeutics that target IL-1⍺ to treat non-dermatological diseases. XBiotech plans to re-enter clinical development expeditiously with a next generation anti-IL-1⍺ therapeutic. Following the acquisition, XBiotech will use its proprietary manufacturing technology...

EDMONTON, Alberta, Dec. 07, 2019 (GLOBE NEWSWIRE) — Athabasca Minerals Inc. (“Athabasca” or the “Corporation”) (TSX Venture: AMI) announces that its Board of Directors have approved the grant of 520,000 stock options (“Options”) and 329,000 Deferred Share Units (“DSUs”) to officers, directors, and select management of the Corporation pursuant to the Corporation’s stock option and DSU plans. The Options have an exercise price of $0.33 per share and have a term of five years.About Athabasca Minerals Inc. (AMI)Athabasca Minerals Inc ( www.athabascaminerals.com), is an integrated group of companies focused on the aggregates and industrial minerals sectors, including resource development, aggregates marketing and midstream supply-logistics solutions. Business activities include aggregate production, sales and royalties from corporate-owned...

100% of evaluable patients in target dose had no relapse during the four-week follow-up periodIndependent objective EEG seizure analysis confirms target doseGanaxolone effective regardless of prior AED treatment and across diverse disease etiologies for RSEKOL call and live webcast on Monday, December 9th at 7:15am ETRADNOR, Pa., Dec. 07, 2019 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, announced additional data from its open-label, dose-finding Phase 2 study evaluating intravenous (IV) ganaxolone in patients with refractory status epilepticus (RSE).  The results were presented at the American Epilepsy Society (AES) annual meeting by Eugene...

AUSTIN, Texas, Dec. 06, 2019 (GLOBE NEWSWIRE) — Jones Energy II, Inc. (OTC: JEII) (“Jones Energy” or the “Company”) today announced that it has entered into a definitive merger agreement to be acquired by Revolution II WI Holding Company, LLC (“Revolution”), an affiliate of Mountain Capital Partners, LP (“Mountain Capital”), in an all-cash transaction valued at approximately $201.5 million. Under the terms of the merger agreement, which has been unanimously approved by the Jones Energy Board of Directors (the “Board”) and a majority of the Jones Energy stockholders, Jones Energy stockholders will receive approximately $14.11 in cash for each share of Jones Energy Class A common stock or each unit of Jones Energy Holdings II, LLC they own, as applicable. The transaction is expected to close in the first quarter of 2020.Jones Energy’s...

Not for Distribution to US Newswire Services or Dissemination in the United StatesLONDON, Ontario, Dec. 06, 2019 (GLOBE NEWSWIRE) — Indiva Limited (the “Company” or “Indiva”) (TSXV:NDVA) (OTCQX:NDVAF) is pleased to announce a strategic partnership with Dycar Pharmaceuticals Ltd. (“Dycar”) and a concurrent non-brokered unsecured convertible debenture financing of up to $4 million.DYCAR PRODUCTION AND DISTRIBUTION PARTNERSHIPIndiva has entered into a financing and white-label manufacturing arrangement with Dycar.  Under the terms of the letter agreement, Dycar will provide Indiva with initial non-dilutive financing of $3.1 million, and Indiva will manufacture and distribute certain Dycar-branded cannabis products from the Company’s licensed facility in London, Ontario.  The financing will be repaid by the deduction of Indiva services...

RICHMOND HILL, Ontario, Dec. 06, 2019 (GLOBE NEWSWIRE) — Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company’s annual and special meeting of shareholders held on December 6, 2019 (the “Meeting”). In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, the following is a summary of the results of matters voted on at the Meeting.There were 20 shareholders represented in person or by proxy at the Meeting holding 83,464,785 common shares, representing approximately 66.80% of Helix’s total issued and outstanding shares.1.           Election of Directors